Ozone inactivation of airborne influenza and lack of resistance of respiratory syncytial virus to aerosolization and sampling processes.
Aerosols
Air Microbiology
Cross Infection
/ prevention & control
Disinfection
/ methods
Humans
Influenza A virus
/ drug effects
Influenza, Human
/ prevention & control
Ozone
/ administration & dosage
Real-Time Polymerase Chain Reaction
Respiratory Syncytial Virus Infections
/ prevention & control
Respiratory Syncytial Viruses
/ drug effects
Virus Inactivation
/ drug effects
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
01
2021
accepted:
26
05
2021
entrez:
12
7
2021
pubmed:
13
7
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Influenza and RSV are human viruses responsible for outbreaks in hospitals, long-term care facilities and nursing homes. The present study assessed an air treatment using ozone at two relative humidity conditions (RHs) in order to reduce the infectivity of airborne influenza. Bovine pulmonary surfactant (BPS) and synthetic tracheal mucus (STM) were used as aerosols protectants to better reflect the human aerosol composition. Residual ozone concentration inside the aerosol chamber was also measured. RSV's sensitivity resulted in testing its resistance to aerosolization and sampling processes instead of ozone exposure. The results showed that without supplement and with STM, a reduction in influenza A infectivity of four orders of magnitude was obtained with an exposure to 1.70 ± 0.19 ppm of ozone at 76% RH for 80 min. Consequently, ozone could be considered as a virucidal disinfectant for airborne influenza A. RSV did not withstand the aerosolization and sampling processes required for the use of the experimental setup. Therefore, ozone exposure could not be performed for this virus. Nonetheless, this study provides great insight for the efficacy of ozone as an air treatment for the control of nosocomial influenza A outbreaks.
Identifiants
pubmed: 34252093
doi: 10.1371/journal.pone.0253022
pii: PONE-D-21-02103
pmc: PMC8274922
doi:
Substances chimiques
Aerosols
0
Ozone
66H7ZZK23N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0253022Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2016 Dec 28;11(12):e0168815
pubmed: 28030577
Int J Infect Dis. 2020 Nov;100:476-482
pubmed: 32949774
BMC Res Notes. 2014 Mar 18;7:158
pubmed: 24642084
J Clin Microbiol. 1983 Sep;18(3):658-62
pubmed: 6313747
J Am Geriatr Soc. 2003 Jun;51(6):761-7
pubmed: 12757561
PLoS One. 2020 Apr 10;15(4):e0231164
pubmed: 32275685
J Hosp Infect. 2007 May;66(1):40-5
pubmed: 17350729
Appl Environ Microbiol. 2018 May 31;84(12):
pubmed: 29625986
Am J Respir Crit Care Med. 1999 Sep;160(3):791-5
pubmed: 10471598
Clin Microbiol Rev. 2001 Jul;14(3):528-46
pubmed: 11432812
J Biomed Mater Res A. 2014 Jun;102(6):1788-98
pubmed: 23813841
Vaccine. 1996 Oct;14(15):1417-20
pubmed: 8994316
PLoS One. 2016 Feb 05;11(2):e0148669
pubmed: 26849130
Environ Sci Pollut Res Int. 2021 Apr;28(13):16517-16531
pubmed: 33389580
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020 May;63(5):645-655
pubmed: 32274539
Am J Respir Crit Care Med. 2016 Aug 1;194(3):308-16
pubmed: 26890617
JAMA. 1999 Oct 20;282(15):1440-6
pubmed: 10535434
J Infect Dis. 2018 Jul 24;218(5):739-747
pubmed: 29878137
Clin Infect Dis. 2010 Mar 1;50(5):693-8
pubmed: 20100093
Clin Infect Dis. 2009 Feb 15;48(4):438-40
pubmed: 19133798
Influenza Other Respir Viruses. 2017 Sep;11(5):356-366
pubmed: 28691237
Ann Intern Med. 1988 Aug 1;109(3):203-8
pubmed: 3389604
Annu Rev Med. 1983;34:311-9
pubmed: 6344761
J Am Geriatr Soc. 1992 Feb;40(2):115-9
pubmed: 1740594
Diagn Microbiol Infect Dis. 2000 Aug;37(4):237-46
pubmed: 10974574
J Virol. 2010 Jul;84(14):7267-77
pubmed: 20410276
Pediatr Infect Dis J. 2005 Dec;24(12):1040-4
pubmed: 16371862
Proc Soc Exp Biol Med. 1968 Jun;128(2):515-8
pubmed: 5663265
J R Soc Interface. 2018 Feb;15(139):
pubmed: 29491178
PLoS One. 2018 Aug 15;13(8):e0202147
pubmed: 30110367
Infect Control Hosp Epidemiol. 1998 Dec;19(12):918-23
pubmed: 9872529
Inhal Toxicol. 2014 Aug;26(9):554-8
pubmed: 25055842
Am J Med. 1981 Mar;70(3):670-6
pubmed: 6259940
AIHA J (Fairfax, Va). 2003 Jul-Aug;64(4):533-7
pubmed: 12908871
Bio Protoc. 2016 May 20;6(10):
pubmed: 30079370
Emerg Microbes Infect. 2020 Dec;9(1):2597-2605
pubmed: 33206022
J Infect Dis. 1995 Aug;172(2):389-94
pubmed: 7622882
J Virol Methods. 1991 Feb-Mar;31(2-3):161-70
pubmed: 1650782
N Engl J Med. 2005 Apr 28;352(17):1749-59
pubmed: 15858184
Pediatr Pulmonol. 2017 May;52(5):684-688
pubmed: 27740722
Appl Environ Microbiol. 2014 Jul;80(14):4242-50
pubmed: 24795379